Suchergebnisse - Dexamethasone OR corticosteroid

PubPharm (12)

1

Clinical review report : (Bausch Health, Canada Inc.) : indication : psoriasis, moderate-to-severe plaqueHalobetasol propionate and tazarotene (Duobrii)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, December 2020

CADTH common drug review

Version: Final (with redactions).

2

Inhaled corticosteroids for cystic fibrosis : a review of clinical effectiveness

Erschienen: Ottawa, CADTH, March 12, 2019

CADTH rapid response report: summary with critical appraisal

Version 1.0.

von Peprah, K. | McCormack, S.

3

Clinical review report : indication : for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and olderCrisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.)

Erschienen: Ottawa (ON), CADTH, April 2019

CADTH common drug review

4

A treatise on topical corticosteroids in dermatology : use, misuse and abuse

Erschienen: Singapore, Springer, [2018]

SpringerLink, Bücher

von Lahiri, K.

5

Omalizumab (Xolair)

Erschienen: Ottawa (ON), CADTH, September 2017

Common drug review clinical review report

6

Clinical review report : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6‐mercaptopurine (6‐MP) or who are intolerant to such therapiesAdalimumab (Humira)

Erschienen: Ottawa (ON), CADTH, April 2016

CADTH common drug review

7

Mepolizumab (Nucala)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, 2016 Nov

Common drug review

8

Development of a brief questionnaire (ICQ-S) to monitor inhaled corticosteroid side-effects in clinical practice

enthalten in: Allergy | 2014

von Foster, J. | Schokker, S. | Sanderman, R. | +2

9

Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs and systemic corticosteroids

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, [2014]

Common drug review

10

Drug class review on beta2-agonists : final report

Erschienen: Portland, Or., Oregon Health & Science University, Evidence-Based Practice Center, c2006

Drug class reviews

von Norris, S.